KPRX News and Press, Kiora Pharmaceuticals Inc. From 04/11/24

Encinitas, California--(Newsfile Corp. - April 11, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) has received grant funding from the Choroideremia Research Foundation (CRF) in support of validating functional vision assessments for patients with profound blindness. Functional vision assess...

Encinitas, California--(Newsfile Corp. - March 28, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced that additional data from the ABACUS-1 trial has been accepted for presentation at the Association for Research in Vision and Ophthalmology (ARVO) meeting ...

Recent Strategic Partnership and Financing Expected to Fund Operations Through 2026 Encinitas, California--(Newsfile Corp. - March 25, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced its 2023 financial results and provided an update on its retinal ...

Encinitas, California--(Newsfile Corp. - March 8, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced the publication of results from a Phase 1 double-masked study of KIO-101, a potent, non-steroidal anti-inflammatory agent. KIO-101 contains the same active ...

A look at the top 10 most actives in the United States PROSHARES TRUST (SQQQ) fell 3.4% to $12.34 on volume of 161,376,033 shares New York Community Bancorp Inc. (NYCB) fell 11.1% to $5.75 on volume of 125,980,698 shares Plug Power Inc. (PLUG) rose 5.6% to $4.7 on volume of 111,112,179 sh...

A look at the top 10 most actives in the United States PROSHARES TRUST (SQQQ) fell 3.3% to $12.36 on volume of 132,876,575 shares New York Community Bancorp Inc. (NYCB) fell 8.1% to $5.945 on volume of 103,690,183 shares Plug Power Inc. (PLUG) rose 2.4% to $4.555 on volume of 100,620,245 ...

2024-01-31 19:03:10 ET More on Kiora Pharmaceuticals Seeking Alpha’s Quant Rating on Kiora Pharmaceuticals Historical earnings data for Kiora Pharmaceuticals Financial information for Kiora Pharmaceuticals Read the full article on Seeking Alpha ...

$15 million in upfront financing with the potential to receive up to an additional approximately $30 million in potential warrant exercise proceeds for an aggregate of up to approximately $45 million in total gross proceeds Encinitas, California--(Newsfile Corp. - January 31, 2024) - Kiora Pharm...

Kiora to webcast investor conference call at 5:30 pm today; details below Encinitas, California and Clermont-Ferrand, France--(Newsfile Corp. - January 31, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), a clinical-stage biotech company developing treatments for orphan retinal disease...

--News Direct-- Kiora Pharmaceuticals CEO Brian Strem joined Steve Darling from Proactive to share news the company's plan to broaden the clinical development of KIO-301, a treatment designed for various inherited retinal diseases. The expansion includes initiating a Phase 2 trial whi...